| A critical appraisal of amyloid-β-targeting therapies for Alzheimer disease F Panza, M Lozupone, G Logroscino, BP Imbimbo Nature Reviews Neurology 15 (2), 73-88, 2019 | 880 | 2019 |
| Relationships of dietary patterns, foods, and micro-and macronutrients with Alzheimer’s disease and late-life cognitive disorders: a systematic review V Solfrizzi, C Custodero, M Lozupone, BP Imbimbo, V Valiani, P Agosti, ... Journal of Alzheimer's Disease 59 (3), 815-849, 2017 | 357 | 2017 |
| Different cognitive frailty models and health-and cognitive-related outcomes in older age: from epidemiology to prevention F Panza, M Lozupone, V Solfrizzi, R Sardone, V Dibello, L Di Lena, ... Journal of Alzheimer's disease 62 (3), 993-1012, 2018 | 295 | 2018 |
| Tau‐Centric Targets and Drugs in Clinical Development for the Treatment of Alzheimer’s Disease F Panza, V Solfrizzi, D Seripa, BP Imbimbo, M Lozupone, A Santamato, ... BioMed research international 2016 (1), 3245935, 2016 | 208 | 2016 |
| Amyloid‐β immunotherapy for alzheimer disease: Is it now a long shot? F Panza, M Lozupone, D Seripa, BP Imbimbo Annals of neurology 85 (3), 303-315, 2019 | 178 | 2019 |
| Reversible cognitive frailty, dementia, and all-cause mortality. The Italian longitudinal study on aging V Solfrizzi, E Scafato, D Seripa, M Lozupone, BP Imbimbo, A D'Amato, ... Journal of the American Medical Directors Association 18 (1), 89. e1-89. e8, 2017 | 155 | 2017 |
| Time to test antibacterial therapy in Alzheimer’s disease F Panza, M Lozupone, V Solfrizzi, M Watling, BP Imbimbo Brain 142 (10), 2905-2929, 2019 | 149 | 2019 |
| Oral frailty and its determinants in older age: a systematic review V Dibello, R Zupo, R Sardone, M Lozupone, F Castellana, A Dibello, ... The Lancet Healthy Longevity 2 (8), e507-e520, 2021 | 143 | 2021 |
| Genetically determined measures of striatal D2 signaling predict prefrontal activity during working memory performance A Bertolino, P Taurisano, NM Pisciotta, G Blasi, L Fazio, R Romano, ... PloS one 5 (2), e9348, 2010 | 117 | 2010 |
| Additive role of a potentially reversible cognitive frailty model and inflammatory state on the risk of disability: the Italian longitudinal study on aging V Solfrizzi, E Scafato, M Lozupone, D Seripa, M Giannini, R Sardone, ... The American Journal of Geriatric Psychiatry 25 (11), 1236-1248, 2017 | 111 | 2017 |
| Sensorial frailty: age-related hearing loss and the risk of cognitive impairment and dementia in later life F Panza, M Lozupone, R Sardone, P Battista, M Piccininni, V Dibello, ... Therapeutic Advances in Chronic Disease 10, 2040622318811000, 2019 | 109 | 2019 |
| Suicidal behaviour in older age: A systematic review of risk factors associated to suicide attempts and completed suicides M Beghi, E Butera, CG Cerri, CM Cornaggia, F Febbo, A Mollica, ... Neuroscience & Biobehavioral Reviews 127, 193-211, 2021 | 108 | 2021 |
| Development of disease-modifying drugs for frontotemporal dementia spectrum disorders F Panza, M Lozupone, D Seripa, A Daniele, M Watling, G Giannelli, ... Nature Reviews Neurology 16 (4), 213-228, 2020 | 105 | 2020 |
| The age-related central auditory processing disorder: silent impairment of the cognitive ear R Sardone, P Battista, F Panza, M Lozupone, C Griseta, F Castellana, ... Frontiers in neuroscience 13, 619, 2019 | 99 | 2019 |
| BACE inhibitors in clinical development for the treatment of Alzheimer’s disease F Panza, M Lozupone, V Solfrizzi, R Sardone, C Piccininni, V Dibello, ... Expert review of neurotherapeutics 18 (11), 847-857, 2018 | 95 | 2018 |
| Tau-based therapeutics for Alzheimer’s disease: active and passive immunotherapy F Panza, V Solfrizzi, D Seripa, BP Imbimbo, M Lozupone, A Santamato, ... Immunotherapy 8 (9), 1119-1134, 2016 | 85 | 2016 |
| Emerging drugs to reduce abnormal β-amyloid protein in Alzheimer’s disease patients F Panza, D Seripa, V Solfrizzi, BP Imbimbo, M Lozupone, A Leo, ... Expert Opinion on Emerging Drugs 21 (4), 377-391, 2016 | 76 | 2016 |
| How gait influences frailty models and health‐related outcomes in clinical‐based and population‐based studies: a systematic review I Bortone, R Sardone, L Lampignano, F Castellana, R Zupo, M Lozupone, ... Journal of cachexia, sarcopenia and muscle 12 (2), 274-297, 2021 | 70 | 2021 |
| Anti-amyloid-β protein agents for the treatment of Alzheimer’s disease: an update on emerging drugs M Lozupone, V Solfrizzi, F D’Urso, I Di Gioia, R Sardone, V Dibello, ... Expert Opinion on Emerging Drugs 25 (3), 319-335, 2020 | 69 | 2020 |
| Are antibodies directed against amyloid-β (Aβ) oligomers the last call for the Aβ hypothesis of Alzheimer's disease? F Panza, M Lozupone, V Dibello, A Greco, A Daniele, D Seripa, ... Immunotherapy 11 (1), 3-6, 2019 | 65 | 2019 |
